Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients

Alka Verma, Verma A, Justin C. Konje, Konje JC
European journal of obstetrics, gynecology, and reproductive biology · 2009 · vol. 143(2) , pp. 112–115 · doi:10.1016/j.ejogrb.2008.12.002 · PMID:19233536 · W2082576784
Case report OA: closed CC0 ⤵ 35 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study investigated the efficacy of aromatase inhibitors in treating refractory endometriosis-related chronic pelvic pain in premenopausal patients, reporting successful outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Not every patient with endometriosis responds to currently recommended conventional medical treatment regimens. The objective of this study was to determine the efficacy and side effects of aromatase inhibitors in the treatment of premenopausal patients with endometriosis associated with chronic pelvic pain refractory to conventional treatment. STUDY DESIGN: Four premenopausal patients with documented refractory endometriosis and chronic pelvic pain were treated with aromatase inhibitors, either anastrazole (3) or letrozole (1), for 6 months. The treatment was combined with calcium 1.5 g per day and vitamin D 800 U per day. The main outcome measure was reduction in pelvic pain assessed by visual analogue scale. Side effects were documented and changes in serum LH, FSH and 17-beta estradiol and bone density (Dexa scan) were measured before, during and after treatment. RESULTS: There was marked improvement in pelvic pain in the four patients. Their mean pain score fell from 9 prior to treatment to 4.5 at the end of treatment. One patient with infertility conceived immediately after completing the treatment. There were no changes in the hormone levels and bone scan scores. The most common side effect was irregular bleeding with anastrazole and joint pains with letrozole. CONCLUSIONS: Aromatase inhibitors are beneficial in premenopausal women with chronic pelvic pain secondary to refractory endometriosis without compromising fertility and with minimal side effects. Further cohort and comparative studies are needed to confirm these observations.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Aromatase Inhibitors Endometriosis Nitriles Pelvic Pain Premenopause Premenopause Triazoles Uterine Diseases Adult Adult Anastrozole Anastrozole Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Chronic Disease Chronic Disease Dose-Response Relationship, Drug Dose-Response Relationship, Drug Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (36)

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:06:15.453410+00:00
unpaywall
last seen: 2026-10-18T06:28:46.490043+00:00
License: CC0 · commercial use OK